Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: AMENDED: * 04-21-91 Zidovudine (AZT) allowed after completing 8 weeks on the study. Patients on reduced doses of VP-16 must have tolerated at least 4 consecutive weeks at the reduced dose before starting AZT. Zidovudine will not be provided by the NIAID Clinical Product Research Repository. AMENDED: * Zidovudine (AZT) allowed after completing 12 weeks on study. Allowed: * Aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis (PCP). Concurrent Treatment: Allowed: * Local radiotherapy or laser therapy to cosmetically apparent, non-indicator lesions provided the dose to any one lesion does not exceed 300 rads and the total surface area of all lesions treated does not exceed 10 cm2. Risk Behavior: Allowed: * All risk groups. Patients must: * Have AIDS-related Kaposi's sarcoma. * Be ineligible for protocols of higher priority at study center. * Be willing to sign an informed consent or have guardian willing to sign. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Active opportunistic infection not specifically allowed. * Concurrent neoplasm not specifically allowed. * Significant neurologic, cardiac, or liver disease. Concurrent Medication: Excluded: * Therapy with potentially myelosuppressive, hepatotoxic, or nephrotoxic drugs for an opportunistic infection. Patients with the following are excluded: * Active opportunistic infection not specifically allowed. * Ongoing therapy, including maintenance therapy, for an opportunistic infection with potentially myelosuppressive, hepatotoxic, or nephrotoxic drugs. * Concurrent neoplasm not specifically allowed. * Significant neurologic, cardiac, or liver disease. Prior Medication: Excluded: * Biologic response modifiers or corticosteroids within 14 days prior to study entry. * Cytotoxic chemotherapy within 30 days prior to study entry. * Ribavirin within 6 weeks prior to study entry. * Azidothymidine (AZT), alpha-interferon, didanosine (ddI), ganciclovir (DHPG), or any other antiretroviral drugs within 1 week prior to study entry. Prior Treatment: Excluded within 30 days prior to study entry: * Radiation therapy with \> 4000 rads. * Total skin electron beam therapy.